JP2009504668A5 - - Google Patents

Download PDF

Info

Publication number
JP2009504668A5
JP2009504668A5 JP2008526210A JP2008526210A JP2009504668A5 JP 2009504668 A5 JP2009504668 A5 JP 2009504668A5 JP 2008526210 A JP2008526210 A JP 2008526210A JP 2008526210 A JP2008526210 A JP 2008526210A JP 2009504668 A5 JP2009504668 A5 JP 2009504668A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
seq
constant region
human immunoglobulin
immunoglobulin constant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008526210A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009504668A (ja
JP5118037B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/031274 external-priority patent/WO2007019573A2/en
Publication of JP2009504668A publication Critical patent/JP2009504668A/ja
Publication of JP2009504668A5 publication Critical patent/JP2009504668A5/ja
Application granted granted Critical
Publication of JP5118037B2 publication Critical patent/JP5118037B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008526210A 2005-08-09 2006-08-09 Taci融合分子を用いた異常細胞増殖の処置及び予防のための方法 Expired - Fee Related JP5118037B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70688805P 2005-08-09 2005-08-09
US60/706,888 2005-08-09
PCT/US2006/031274 WO2007019573A2 (en) 2005-08-09 2006-08-09 Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules

Publications (3)

Publication Number Publication Date
JP2009504668A JP2009504668A (ja) 2009-02-05
JP2009504668A5 true JP2009504668A5 (enExample) 2009-09-17
JP5118037B2 JP5118037B2 (ja) 2013-01-16

Family

ID=37670706

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008526210A Expired - Fee Related JP5118037B2 (ja) 2005-08-09 2006-08-09 Taci融合分子を用いた異常細胞増殖の処置及び予防のための方法

Country Status (9)

Country Link
US (1) US8808696B2 (enExample)
EP (1) EP1922079A2 (enExample)
JP (1) JP5118037B2 (enExample)
AR (1) AR059025A1 (enExample)
AU (1) AU2006278227B2 (enExample)
CA (1) CA2618763A1 (enExample)
IL (1) IL188404A (enExample)
NO (1) NO20081152L (enExample)
WO (1) WO2007019573A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
CN101262876A (zh) 2005-08-09 2008-09-10 酶遗传学股份有限公司 用taci-ig融合分子治疗b细胞恶性肿瘤的方法
WO2007019573A2 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
CN101489573B (zh) 2006-05-15 2013-05-22 阿雷斯贸易股份有限公司 用TACI-Ig融合分子治疗自身免疫疾病的方法
CN101323643B (zh) * 2007-06-15 2010-12-01 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白
US20170247462A1 (en) 2014-07-03 2017-08-31 Oklahoma Medical Research Foundation Treatment of multiple sclerosis and neuromyelitis optica
WO2019074983A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
WO2021226551A1 (en) 2020-05-08 2021-11-11 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins and methods of use thereof
CN116897159A (zh) * 2021-03-31 2023-10-17 江苏恒瑞医药股份有限公司 截短的taci多肽及其融合蛋白和用途

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
AU560472B2 (en) 1981-08-25 1987-04-09 Celltech Limited Yeast expression vectors
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
EP0184576B1 (en) 1984-12-06 1990-06-27 Fina Research S.A. Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides
US4751181A (en) 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
US5637677A (en) 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
EP0721983A1 (en) 1988-01-22 1996-07-17 ZymoGenetics, Inc. Methods of producing biologically active peptide dimers
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
ES2152920T3 (es) 1990-02-09 2001-02-16 Salk Inst For Biological Studi Composiciones receptoras de retinoides y metodos.
US5208146A (en) 1990-11-05 1993-05-04 The Regents Of The University Of California Murine monoclonal anti-idiotype antibodies
CA2144651A1 (en) 1992-09-14 1994-03-31 Timothy J. Miller Immortalized cells and uses therefor
WO1994009137A1 (en) 1992-10-15 1994-04-28 Genentech, Inc. Antibodies against type 2 tumor necrosis factor receptor
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5650550A (en) 1993-10-01 1997-07-22 The United States Of America As Represented By The Department Of Health And Human Services Mutant mice having a deficit of functional estrogen receptors
US5523227A (en) 1994-06-17 1996-06-04 The Board Of Trustees Of The Leland Stanford Junior Univ. DNA encoding calcium-signal modulating cyclophilin ligand
MX9704501A (es) 1994-12-15 1997-10-31 Yeda Res & Dev Moduladores de la funcion de receptores de fas/ap01.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE19533447C1 (de) 1995-09-09 1996-12-05 Bbs Kraftfahrzeugtechnik Verfahren und Vorrichtung zum Befüllen eines Gießwerkzeugs mit einer Metallschmelze
WO1997017450A2 (en) 1995-11-09 1997-05-15 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in pichia methanolica
US5716808A (en) 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
EP1362916A3 (en) 1996-03-14 2004-02-18 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
CN1238806A (zh) 1996-07-17 1999-12-15 津莫吉尼蒂克斯公司 甲醇毕赤酵母营养突变体的制备
WO1998002565A1 (en) 1996-07-17 1998-01-22 Zymogenetics, Inc. TRANSFORMATION OF $i(PICHIA METHANOLICA)
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US6689579B1 (en) * 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
DK0939804T4 (da) 1996-10-25 2011-07-18 Human Genome Sciences Inc Neutrokin-alpha
WO1998027114A2 (en) 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
CA2292899A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
IL133315A0 (en) 1997-06-06 2001-04-30 Regeneron Pharma Ntn-2 member of tnf ligand family
WO1999004001A1 (en) 1997-07-21 1999-01-28 Zymogenetics, Inc. Tumor necrosis factor receptor ztnfr-5
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
BR9812634A (pt) 1997-09-12 2000-08-22 Biogen Inc April - uma proteìna com efeitos de crescimento
IL134480A0 (en) 1997-09-12 2001-04-30 Apotech Sa Kay - an immune system protein and dna sequences encoding the same
DE19831987A1 (de) 1998-07-16 2000-01-20 Bayer Ag Diphenylimidazoline
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
EP1141278B1 (en) * 1998-12-30 2008-02-27 Oligos Etc. Inc. Therapeutic pde4d phosphodiesterase inhibitors
US20060067933A1 (en) * 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
US7833529B1 (en) * 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
TR200101998T2 (tr) * 1999-01-07 2002-06-21 Zymogenetics, Inc. Çözünür reseptör BR 43x2 ve kullanım metodları
ATE515267T1 (de) 1999-01-25 2011-07-15 Biogen Idec Inc Verwendung eines antikörpers gegen wasserlöslich baff zur krebsbehandlung
EP1860190A3 (en) 1999-02-23 2008-03-12 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variants
CA2366785C (en) 1999-04-19 2012-02-07 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20030022233A1 (en) * 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
EP1180159B1 (en) * 1999-05-28 2008-09-03 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders
PL211786B1 (pl) 1999-08-17 2012-06-29 Apoxis Sa Zastosowanie przeciwciała oraz polipeptydu
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU2048501A (en) 2000-02-16 2001-08-27 Genentech Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
US20040013674A1 (en) * 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
AU2001253920B2 (en) 2000-04-27 2006-03-16 Apoxis Sa Use of taci as an anti-tumor agent
DE60128216T2 (de) 2000-05-12 2008-01-10 Amgen Inc., Thousand Oaks Polypeptide zum Hemmen der April-vermittelten Proliferation von B- und T- Zellen
WO2001094419A2 (en) * 2000-06-07 2001-12-13 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method to induce the th1 immune response
JP2004516826A (ja) 2000-11-07 2004-06-10 ザイモジェネティクス,インコーポレイティド ヒト腫瘍壊死因子受容体
CA2438682A1 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
EA010594B1 (ru) 2001-05-24 2008-10-30 Займодженетикс, Инк. Слитые белки taci-иммуноглобулина
CA2453995A1 (en) 2001-08-03 2003-02-20 Genentech, Inc. Tacis and br3 polypeptides and uses thereof
WO2003097040A1 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US7090417B2 (en) * 2002-10-29 2006-08-15 Eastman Kodak Company Method of programming pages within a document to be printed on different output devices
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
PT2272868E (pt) 2003-06-05 2015-07-07 Genentech Inc Terapêutica de combinação para distúrbios de células b
RU2006117324A (ru) * 2003-10-20 2007-12-10 Байоджен Айдек Ма Инк. (Us) Терапевтические режимы для антагонистов baff
FR2884251B1 (fr) 2005-04-08 2007-07-13 Servier Lab Derives de piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN101262876A (zh) 2005-08-09 2008-09-10 酶遗传学股份有限公司 用taci-ig融合分子治疗b细胞恶性肿瘤的方法
WO2007019573A2 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
US8637021B2 (en) 2007-11-12 2014-01-28 Ares Trading S.A. Formulations for TACI-immunoglobulin fusion proteins

Similar Documents

Publication Publication Date Title
JP2009519257A5 (enExample)
JP2007529421A5 (enExample)
JP2011520977A5 (enExample)
JP2010518079A5 (enExample)
JP2014534265A5 (enExample)
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
JP2014500295A5 (enExample)
JP2016539156A5 (enExample)
JP2015522630A5 (enExample)
JP2009537563A5 (enExample)
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
WO2011052888A3 (ko) (3-플루오로-2-히드록시)프로필 작용기가 도입된 아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
CN101959513A (zh) 新的药物组合物
JP2019511529A5 (enExample)
CN103533940A (zh) 治疗晚期实体瘤的方法
JP2011518168A5 (enExample)
TW201105341A (en) Pharmacetical composition for inhibitng pain
JP2010500284A5 (enExample)
JP2009507777A5 (enExample)
JP2007536279A5 (enExample)
JP2012504584A5 (enExample)
JP2014522414A5 (enExample)
JP2011508727A5 (enExample)
RU2011111117A (ru) Лечение аутоиммунных заболеваний
TW200306185A (en) Combinations comprising EPOTHILONES and anti-metabolites